The challenge of predicting kidney failure in high-risk populations has long been a hurdle in precision medicine, particularly for individuals of African ancestry. However, a breakthrough study published in Nature Medicine has introduced a novel proteomic tool that can identify those most likely to progress toward chronic kidney disease long before traditional clinical markers signal a crisis.
Researchers have developed a nine-protein plasma signature known as the APOL1 Proteomic Risk Score (APRS). This tool is specifically designed for individuals carrying high-risk genotypes of the APOL1 (apolipoprotein L1) gene who still maintain a preserved estimated glomerular filtration rate (eGFR)—meaning their kidney function appears normal by standard tests. By analyzing proteins in the blood, the APRS can predict future kidney events and mortality with significantly higher accuracy than existing genetic or clinical tools.
This development represents a critical shift in how clinicians may approach APOL1-mediated kidney disease. For years, the medical community has known that APOL1 risk variants are strongly associated with kidney failure in people of African ancestry, but the “trigger” that causes some carriers to develop disease while others remain healthy has remained elusive. The APRS provides a biologically plausible way to bridge that gap, offering a window for early intervention and the potential to reduce systemic health disparities.
Understanding the APOL1 Genetic Risk
The APOL1 gene is a primary driver of racial disparities in kidney health. Individuals who carry two high-risk alleles—known as G1 and/or G2—face a markedly increased risk of kidney failure. It is estimated that 4–5 million African Americans and tens of millions of people worldwide carry this high-risk genotype. While the majority of these carriers remain disease-free, approximately one in five progresses to kidney failure, a rate substantially higher than those with zero or one risk allele.
The impact of this genetic susceptibility is profound. In the United States, individuals of African ancestry develop kidney failure at nearly four times the rate of those of European ancestry. This disparity is fueled by a combination of genetic susceptibility and social determinants of health, including unequal access to quality care.
Until now, the primary limitation for treating these patients has been timing. By the time a patient shows a decline in eGFR or an increase in albuminuria (protein in the urine), significant kidney damage may have already occurred. The APRS aims to identify high-risk individuals while their kidney function is still preserved (eGFR ≥60 ml min−1 1.73 m−2), allowing for preventative strategies before the onset of irreversible damage.
The Science Behind the Nine-Protein Signature
To create the APRS, researchers profiled the plasma proteomes of 851 participants of African ancestry from the Penn Medicine BioBank, consisting of 285 males and 566 females. All participants carried high-risk APOL1 genotypes and had preserved kidney function at the start of the study.
Using a sophisticated statistical method called elastic net Cox regression—adjusted for age, sex, eGFR, and albuminuria—the team identified a specific set of nine proteins that together formed a predictive signature. This signature was used to predict a composite outcome consisting of a ≥40% eGFR decline, kidney failure, or death.
The results demonstrated that the APRS significantly outperformed existing tools:
- APRS Performance: Achieved a time-dependent area under the receiver operating characteristic curve (tAUC) of 86.5%.
- Clinical Baseline: The Kidney Failure Risk Equation, a standard clinical tool, achieved a tAUC of only 66.1%.
- Risk Stratification: The study found a stark difference in outcomes based on the score, with 10-year event rates of 62.5% in the highest risk quintile compared to just 3.3% in the lowest.
The accuracy of the score was further validated in external cohorts, including the UK Biobank and the Atherosclerosis Risk in Communities study, where the tAUC remained robust between 82% and 85%.
Biological Plausibility and Tissue Connection
Crucially, the APRS is not just a statistical correlation. The researchers found that the levels of these nine proteins in the plasma correlated with actual kidney tissue fibrosis and tubular injury pathways. So the blood test is reflecting real, physical changes occurring within the kidney architecture, providing a biological basis for the score’s predictive power.
Implications for Precision Medicine and Treatment
The ability to identify “fast progressors” among APOL1 high-risk carriers opens the door for a new era of precision medicine. One of the most promising applications is the enrichment of clinical trials. By using the APRS to select participants who are at the highest risk of progression, pharmaceutical companies can design smaller, more efficient trials for APOL1-targeted therapies.
Currently, investigational inhibitors such as inaxaplin are being developed to target APOL1 biology and prevent kidney failure. However, administering such therapies to every high-risk carrier would be impractical and potentially expose low-risk individuals to unnecessary side effects. The APRS allows clinicians to target these emerging therapies toward the individuals who need them most.
Beyond drug development, this tool provides a framework for intensified monitoring. Patients identified as high-risk via the APRS could receive more frequent screenings, stricter blood pressure management, and earlier referrals to nephrology specialists, potentially delaying or preventing the transition to end-stage kidney disease.
The Economic and Social Burden of Kidney Failure
The urgency of this research is underscored by the staggering cost and human toll of kidney failure. End-stage kidney disease (ESKD) requires life-sustaining dialysis or a kidney transplant. Globally, chronic kidney disease is estimated to affect more than 800 million people.
In the United States, the financial burden is immense. Medicare expenditures for kidney-related care exceeded $52 billion in 2021. The per-person cost for those with kidney failure is more than twice that of patients without the condition, creating a massive economic strain on both the healthcare system and individual families.
By shifting the focus from treating kidney failure to predicting and preventing it, the APRS could potentially reduce these costs and, more importantly, improve the quality of life for millions of people globally.
Key Takeaways: The APRS Breakthrough
- Target Population: Individuals of African ancestry with high-risk APOL1 genotypes and currently normal kidney function.
- The Tool: A nine-protein plasma signature (APRS) that predicts kidney events and mortality.
- Superiority: Outperforms the Kidney Failure Risk Equation (86.5% tAUC vs 66.1% tAUC).
- Clinical Utility: Enables the identification of high-risk patients for early intervention and the employ of targeted therapies like inaxaplin.
- Biological Link: Protein levels correlate directly with kidney fibrosis and tubular injury.
What Happens Next?
The transition of the APRS from a research finding to a bedside clinical tool will require further integration into standard care pathways. The next critical steps involve the potential implementation of this proteomic screening in larger clinical settings and the results of ongoing trials for APOL1 inhibitors.
As these therapies move toward regulatory approval, the ability to precisely identify the target population will be the deciding factor in their success. Patients and providers are encouraged to monitor updates from the Nature Medicine publication and official announcements from the University of Pennsylvania Health System regarding the availability of these screening tools.
Do you have questions about genetic risk and kidney health? Share your thoughts in the comments below or share this article with others who may find this medical innovation impactful.